High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Germinoma

abstract

  • High-dose carboplatin, etoposide, and cyclophosphamide is an effective therapy for patients with refractory GCT, and results in a complete response proportion of 40% and a 2-year survival rate of 31% at a median follow-up time of 28 months. This was accomplished in a group of patients with a dismal prognosis to conventional-dose therapy.

publication date

  • April 1996

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8648363

Additional Document Info

start page

  • 1098

end page

  • 105

volume

  • 14

number

  • 4